Digital Pattern Recognition-based Image Analysis Quantifies Immune Infiltrates in Distinct Tissue Regions of Colorectal Cancer and Identifies a Metastatic Phenotype

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Aug 22

PMID 23963148

Citations 17

Authors

H K Angell

N Gray

C Womack

D I Pritchard

R W Wilkinson

M Cumberbatch

Affiliations

Soon will be listed here.

Abstract

Background: Several studies in colorectal cancer (CRC) indicate a relationship between tumour immune infiltrates and clinical outcome. We tested the utility of a digital pattern recognition-based image analysis (DPRIA) system to segregate tissue regions and facilitate automated quantification of immune infiltrates in CRC.

Methods: Primary CRC with matched hepatic metastatic (n=7), primary CRC alone (n=18) and primary CRC with matched normal (n=40) tissue were analysed immunohistochemically. Genie pattern recognition software was used to segregate distinct tissue regions in combination with image analysis algorithms to quantify immune cells.

Results: Immune infiltrates were observed predominately at the invasive margin. Quantitative image analysis revealed a significant increase in the prevalence of Foxp3 (P<0.0001), CD8 (P<0.0001), CD68 (<0.0001) and CD31 (<0.0001) positive cells in the stroma of primary and metastatic CRC, compared with tumour cell mass. A direct comparison between non-metastatic primary CRC (MET-) and primary CRC that resulted in metastasis (MET+) showed an immunosuppressive phenotype, with elevated Foxp3 (P<0.05) and reduced numbers of CD8 (P<0.05) cells in the stroma of MET+ compared with MET- samples.

Conclusion: By combining immunohistochemistry with DPRIA, we demonstrate a potential metastatic phenotype in CRC. Our study accelerates wider acceptance and use of automated systems as an adjunct to traditional histopathological techniques.

Citing Articles

Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression.

Fassler D, Torre-Healy L, Gupta R, Hamilton A, Kobayashi S, Van Alsten S Cancers (Basel). 2022; 14(9).

PMID: 35565277 PMC: 9105398. DOI: 10.3390/cancers14092148.

Poor Endometrial Proliferation After Clomiphene is Associated With Altered Estrogen Action.

Hawkins Bressler L, Fritz M, Wu S, Yuan L, Kafer S, Wang T J Clin Endocrinol Metab. 2021; 106(9):2547-2565.

PMID: 34058008 PMC: 8372647. DOI: 10.1210/clinem/dgab381.

Next-Generation Digital Histopathology of the Tumor Microenvironment.

Mungenast F, Fernando A, Nica R, Boghiu B, Lungu B, Batra J Genes (Basel). 2021; 12(4).

PMID: 33917241 PMC: 8068063. DOI: 10.3390/genes12040538.

A template to quantify the location and density of CD3 + and CD8 + tumor-infiltrating lymphocytes in colon cancer by digital pathology on whole slides for an objective, standardized immune score assessment.

Lea D, Watson M, Skaland I, Hagland H, Lillesand M, Gudlaugsson E Cancer Immunol Immunother. 2021; 70(7):2049-2057.

PMID: 33439293 PMC: 8195795. DOI: 10.1007/s00262-020-02834-y.

Analysis of Spatial Distribution and Prognostic Value of Different Pan Cytokeratin Immunostaining Intensities in Breast Tumor Tissue Sections.

Vranes V, Vujasinovic T, Rajkovic N, Kanjer K, Milosevic N, Radulovic M Int J Mol Sci. 2020; 21(12).

PMID: 32580421 PMC: 7352516. DOI: 10.3390/ijms21124434.

References

Ruffell B, DeNardo D, Affara N, Coussens L . Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2009; 21(1):3-10. PMC: 2834837. DOI: 10.1016/j.cytogfr.2009.11.002. View

Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T . Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity. 2007; 27(1):145-59. DOI: 10.1016/j.immuni.2007.04.017. View

Colombo M, Piconese S . Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007; 7(11):880-7. DOI: 10.1038/nrc2250. View

DeNardo D, Brennan D, Rexhepaj E, Ruffell B, Shiao S, Madden S . Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1(1):54-67. PMC: 3203524. DOI: 10.1158/2159-8274.CD-10-0028. View

Galon J, Fridman W, Pages F . The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007; 67(5):1883-6. DOI: 10.1158/0008-5472.CAN-06-4806. View

Erreni M, Mantovani A, Allavena P . Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron. 2011; 4(2):141-54. PMC: 3170420. DOI: 10.1007/s12307-010-0052-5. View

Mantovani A, Sozzani S, Locati M, Allavena P, Sica A . Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23(11):549-55. DOI: 10.1016/s1471-4906(02)02302-5. View

Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G . Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011; 71(4):1263-71. DOI: 10.1158/0008-5472.CAN-10-2907. View

Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G . In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009; 27(35):5944-51. DOI: 10.1200/JCO.2008.19.6147. View

10.

Galon J, Pages F, Marincola F, Thurin M, Trinchieri G, Fox B . The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012; 10:1. PMC: 3269368. DOI: 10.1186/1479-5876-10-1. View

11.

Lin E, Li J, Bricard G, Wang W, Deng Y, Sellers R . Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol. 2008; 1(3):288-302. PMC: 2396497. DOI: 10.1016/j.molonc.2007.10.003. View

12.

Halama N, Michel S, Kloor M, Zoernig I, Pommerencke T, von Knebel Doeberitz M . The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun. 2009; 9:1. PMC: 2935770. View

13.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D . Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2008; 27(2):186-92. DOI: 10.1200/JCO.2008.18.7229. View

14.

Pages F, Galon J, Fridman W . The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol. 2008; 84(4):981-7. DOI: 10.1189/jlb.1107773. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Shimizu J, Yamazaki S, Sakaguchi S . Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163(10):5211-8. View

17.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

18.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

19.

Bui J, Uppaluri R, Hsieh C, Schreiber R . Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 2006; 66(14):7301-9. DOI: 10.1158/0008-5472.CAN-06-0556. View

20.

Woo E, Chu C, Goletz T, Schlienger K, Yeh H, Coukos G . Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001; 61(12):4766-72. View